Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 7/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100201 | 0.85 | L3MBTL1 (0.37) | L3MBTL1ELANEPOLBGPR119BCHE | |
| SCHEMBL26615777 | 0.84 | L3MBTL1 (0.39) | L3MBTL1ELANEPOLBGPR119BCHE | |
| SCHEMBL24721570 | 0.81 | L3MBTL1 (0.39) | L3MBTL1GPR119BCHEMEN1KMT2A | |
| SCHEMBL29361217 | 0.78 | L3MBTL1 (0.33) | L3MBTL1ELANEPOLBGPR119BCHE | |
| SCHEMBL25028610 | 0.78 | L3MBTL1 (0.33) | L3MBTL1ELANEPOLBGPR119BCHE | |
| SCHEMBL19100666 | 0.75 | ACLY (0.44) | GPR119BCHEMEN1TSHRKMT2A | |
| SCHEMBL31186267 | 0.75 | L3MBTL1 (0.55) | L3MBTL1ELANEPOLBMAPTIMPDH2 | |
| SCHEMBL19100397 | 0.74 | AAK1 (0.41) | ELANEPOLBGPR119 | |
| SCHEMBL14222808 | 0.74 | L3MBTL1 (0.57) | L3MBTL1BCHEMEN1KMT2ABRD4 | |
| SCHEMBL29005571 | 0.73 | ELANE (0.33) | L3MBTL1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204235-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220306609-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306609-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NCOA3 | L3MBTL1 4313/4885ELANE 3737/4885POLB 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.